Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Reduction of clinical parameters by liposomal dexamethasone phosphate on Days 19 and 28 of adjuvant arthritis

From: Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis

Experiment 1 Arthritis score Paw volume
   Treatment Day 19 Day 28 Day 19 Day 28
   AA/PBS -- -- -- --
   AA/PBS-liposomes +23% ± 29.4% +36% ± 56.5% + 2% ± 38.8% +47% ± 62.3%
   AA/DxM-P -51% ± 17.8% + 4% ± 41.7% -65% ± 14.0% -13% ± 26.4%
   AA/liposomal DxM-P -95% ± 3.2%++ ## -54% ± 28.7% -92% ± 7.4%++ # -73% ± 17.3% +
Experiment 2/3 Arthritis score Paw volume
   Treatment Day 19 Day 29* Day 19 Day 29*
   AA/PBS -- -- -- --
   AA/PBS-liposomes +15% ± 19.8%   +23% ± 20.3%  
   AA/DxM-P -67% ± 16.4% + #   -52% ± 21.8% + #  
   AA/liposomal DxM-P -90% ± 5.0%++ ##   -87% ± 6.6.%++ ##  
   AA/liposomal DxM-P 1× * -48% ± 23.9% -15% ± 29.6% -63% ± 24.6% -35% ± 22.6%
  1. Reduction of arthritis score and paw volume on Day 19 (maximal efficacy of therapy) and Day 28 of AA after treatment with PBS-liposomes, free DxM-P (3 × 1 mg/kg; Days 14, 15 and 16), or liposomal DxM-P (3 × 1 mg/kg; Days 14, 15 and 16) compared to AA/PBS (Experiment 1 corresponds to the data in Figure 1). For comparison, the effects of treatment with single-dose liposomal DxM-P (1 × 1 mg/kg; Day 14; Experiment 3) are shown. * results from a separate subgroup of animals (named Experiment 3 for clarity) from the same arthritis study with similar disease severity on Days 19 and 20 as the other subgroup of animals (named Experiment 2).
  2. Data are expressed as means ± standard error of the mean.
  3. + P ≤ 0.05, ++ P ≤ 0.01 vs. AA/PBS; # P ≤ 0.05, ## P ≤ 0.01 vs. PBS-liposomes.